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INTRODUCTION
Multiple myeloma (MM) is a malignant plasma cell dis-
order accounting for ~10% of hematological malignancies
that frequently involves old age patients. The incidence of
multiple myeloma has been increasing since the 1980s in
Korea (1). Treatment options for patients with symptomatic
MM range from relatively simple conventional chemothera-
py to high-dose chemotherapy followed by peripheral stem
cell or bone marrow transplantation (2).
For the last several decades, conventional chemotherapy
using melphalan and prednisolone was the mainstay of myelo-
ma treatment that produced response rates of 50-60%. But,
complete remission (CR) was less than 5%, and median remis-
sion duration and overall survival (OS) were 18 and 30-36
months (3, 4). There is no evidence that additional cytotox-
ic agents, such as doxorubicin and nitrosourea, offer survival
advantages compared with that achieved with melphalan and
prednisolone (5). High-dose chemotherapy followed by hema-
topoietic stem cell transplantation has been shown to increase
the percentage of CR to almost 50% in selected patients.
Although conventional chemotherapy and high-dose thera-
py with hematopoietic stem cell rescue can prolong survival,
few, if any, patients are cured (6-10). However, salvage ther-
apies for these patients with relapsed or refractory MM are
disappointing, and although thalidomide has shown some
promise (11-15), more effective treatment strategies are urgent-
ly required. 
Recent clinical trials showed that bortezomib (Velcade
�,
formerly PS341), a novel proteasome inhibitor, had thera-
peutic activity in patients with relapsed or refractory myelo-
ma (16, 17). Richardson et al. reported that the response rate
to bortezomib was 35% and a median duration of response
was 12 months in relapsed or refractory myeloma (16). How-
ever, only 2 phase II clinical trials that showed the efficacy
of bortezomib in myeloma patients were published (16, 17)
and no data is available upon bortezomib in Korean patients
with relapsed or refractory MM. Therefore, a pilot study of
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A Pilot Study of Bortezomib in Korean Patients with Relapsed or
Refractory Myeloma 
Recent clinical trials showed that bortezomib, a novel proteasome inhibitor, had
therapeutic activity in multiple myeloma. However, there was no data about the
feasibility of bortezomib in Korean patients. We performed a pilot study of borte-
zomib in patients with relapsed or refractory myeloma (1.3 mg/m
2 twice weekly for
2 week in a 3-week cycle). Seven patients were enrolled. The median age of
patients was 59 yr. All patients previously received VAD (vincristine, doxorubicin
and dexamethasone) and thalidomide chemotherapy. Three patients previously
received alkylator-containing chemotherapy and 4 patients, autologous stem cell
transplantation. Bortezomib monotherapy resulted in 3 partial remissions (43%), 3
no changes (43%) and 1 progressive disease (14%). One patient who had no
response to bortezomib monotherapy experienced partial remission after addition
of dexamethasone to bortezomib. The most common serious toxicity was throm-
bocytopenia (grade 3/4, 10 of 20 cycles (50%)) and grade 3 peripheral neuropathy
was developed in 2 of 20 cycles (10%). Drug-related adverse event led to discon-
tinuation of bortezomib in 1 patient. There was no treatment related mortality. Over-
all, bortezomib seems to be effective and feasible. Conduction of larger clinical
studies on Korean patients is necessary to characterize clinical efficacy and safety
of bortezomib more precisely.
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bortezomib in these myeloma patients was conducted in 3
institutions. This pilot study aimed to assess the feasibility
of bortezomib in Korean patients. 
PATIENTS AND METHODS
Patients
The eligibility criteria for patients were as follows; 1) patient
age ≥18 yr, 2) multiple myeloma which was relapsed or re-
fractory to previous chemotherapy or autologous stem cell
transplantation, 3) patients with measurable disease [M-pro-
tein], 4) an ECOG performance status of 0-3, 5) aspartate
aminotransferase or alanine aminotransferase ≤3× upper
limit of normal, and total bilirubin ≤2× upper limit of
normal, 6) creatinine clearance ≥10 mL/min, 7) platelet count
≥30×10
9/L, hemoglobin ≥8.0 g/dL and absolute neutro-
phil count ≥0.5×10
9/L. All patients gave written informed
consent before study entry. 
Treatment
Patients received bortezomib (Velcade
�, 1.3 mg per square
meter of body-surface area) as an intravenous bolus (taking
3 to 5 sec to administer) twice weekly for 2 weeks (days 1,
4, 8 and 11) in a 21-day cycle. Treatment was withheld from
patients with drug-related grade 3 or worse non-hematolog-
ic adverse events or grade 4 hematologic adverse events until
the events had diminished to grade 1 or better. Then, treat-
ment was resumed at a dose of 1.0 mg per square meter upon
resolution of the adverse events. Further reduction to 0.7 mg
per square meter was allowed, but lower doses were not per-
mitted. Patients with no change or progressive disease after
2 cycles were permitted to receive 20 mg of oral or intravenous
dexamethasone on the day of and the day following each dose
of bortezomib. 
Assessment of efficacy and safety
The primary end-point was overall response rate to borte-
zomib. Response to bortezomib was evaluated according to
the criteria of the European Group for Blood and Marrow
Transplantation (EBMT) (18) before initiation of each borte-
zomib chemotherapy cycle. Complete remission (CR) was
defined as the absence of M-protein on immunofixation (or
immunoelectrophoresis) for 6 weeks and 5% or fewer plasma
cells in the bone marrow, with no increase in size or number
of bone lesions and the disappearance of soft tissue plasmacy-
tomas. Partial remission (PR) was defined as ≥50% decrease
of serum M-protein and/or ≥90% decrease of urine M-pro-
tein for 6 weeks, with no increase in size or number of bone
lesions. Minimal response (MR) was defined as 25-49% de-
crease of serum M-protein and/or 50-89% reduction in urine
M-protein, which still exceeded 200 mg/day for 6 weeks. No
change (NC) was defined as not meeting the criteria of either
minimal response or progressive disease, and progressive dis-
ease (PD) was defined as ≥25% increase of serum M-protein,
which must have represented an absolute increase of at least
0.5 g/dL, and/or ≥25% increase of urine M-protein, which
must have represented an absolute increase of at least 200
mg/day and have been confirmed by at least one repeated test.
Adverse events were graded according to the National Can-
cer Institute Common Toxicity Criteria, version 2.0, from
the first dose until 20 days after the last dose of bortezomib. 
Statistical analysis
Time to progression (TTP) was defined as the interval from
the initial administration of bortezomib to disease progres-
sion. Overall survival (OS) was defined as the time elapsed
from the onset of bortezomib to death whatever the cause of
death. Distributions over time were estimated by Kaplan-
Meier analysis.
RESULTS
Patient characteristics
Seven patients were accrued onto this study between Novem-
ber 2003 and April 2004 from 3 centers. All 7 patients had
measurable serum M-protein amount. The median age was
59 yr (range: 57-67 yr). All patients previously received VAD
(vincristine, doxorubicin and dexamethasone) and thalido-
mide (±dexamethasone) chemotherapy. Three patients pre-
viously received alkylator-containing chemotherapy and 4
patients received autologous peripheral blood stem cell trans-
plantation. Table 1 shows the summary of base-line charac-
teristics and treatment courses of enrolled patients. 
Treatment and efficacy
A total of 20 cycles of bortezomib and/or dexamethasone
treatment was performed (Table 1). Among 3 patients who
experienced NC after 2 cycles of bortezomib treatment, dex-
amethasone was added to the bortezomib treatment regimen
in 2 patients (case 4 and 6) in cycle 3. Two patients (case 3 and
7) received only one cycle of bortezomib; additional borte-
zomib chemotherapy was not performed in one patient (case
7) because of disease progression and the other (case 3) received
tandem autologous stem cell transplantation after achieve-
ment of PR following one cycle of bortezomib. Two patients
(case 2 and 5) received 2 cycles of bortezomib; one patient (case
2) dropped out of the study because of the economic problem
for the treatment and the other patient (case 5) with the res-
ponse of NC after 2 cycles of bortezomib received other sal-
vage chemotherapy. As shown in Table 1, 3 patients (43%)600 K.-W. Lee, T. Yun, E.K. Song, et al.
achieved PR. Three patients (43%) experienced NC and one
patient (14%), PD. Among 2 patients who experienced NC
after 2 cycles of bortezomib monotherapy and received addi-
tional dexamethasone in cycle 3, 1 patient (case 6) achieved
PR after the addition of dexamethasone. So, overall response
to bortezomib and/or dexamethasone was 57%. 
Adverse events
Commonly reported adverse events in this pilot study are
shown in Table 2. Thrombocytopenia, emesis, leucopenia,
anemia, peripheral neuropathy and hepatic enzyme elevation
were common. Emesis was mild to moderate and easily man-
ageable with routine support. The most commonly reported
serious adverse event was thrombocytopenia (grade 3/4, 10 of
20 cycles (50%) and 4 of 7 patients (57%)). Grade 3 periph-
eral neuropathy developed in 2 of 20 cycles (10%) and 1 of
7 patients (14%). There was no treatment related mortality.
Drug-related adverse event led to discontinuation of borte-
zomib therapy in 1 patient (case 6). After 2 cycles of borte-
zomib monotherapy and 4 cycles of bortezomib/dexametha-
sone combination, this patient suffered from severe pneumo-
nia and needed mechanical ventilation care. After recovery,
peripheral neuropathy (grade 3) persisted and further adminis-
tration of bortezomib was not done. 
Time to progression and overall survival
Median follow-up duration was 10.5 months (range 6.4-
11.2 months). During follow-up period, four cases (57%)
showed increased M-protein amount (disease progression)
during or after the completion of bortezomib and/or dexam-
ethasone treatment. Other two patients received another treat-
ment after documentation of PR (case 3) and NC (case 5).
These two patients (case 3 and 5) were considered as ‘censored’
cases in this study. Only one case (case 2) was in the status
of continuous PR at the last follow-up. When time to pro-
gression (TTP) was defined as the interval from the initial
administration of bortezomib to disease progression, medi-
an TTP in patients who received bortezomib and/or dexam-
ethasone was 5.1 months (95% confidence interval: 3.3-6.9
months). During the follow-up period, four patients (57%)
were still alive and three patients died. Cause of death was
disease progression in all three patients (Table 1). 
DISCUSSION
The proteasome is a multi-enzyme complex that is present
in all cells. It degrades proteins that regulate cell-cycle pro-
gression (19, 20) and causes proteolysis of I B the endoge-
nous inhibitor of nuclear factor- B (NF- B). Degradation of
I B by proteasome activates NF- B, which up-regulates the
*Abbreviations: APBSCT, autologous peripheral blood stem cell transplantation; B, bortezomib; BD, bortezomib/dexamethasone; CD, cyclophos-
phamide/dexamethasone; DCEP, dexamethasone/cyclophosphamide/etoposide/cisplatin; EDAP, etoposide/dexamethasone/ara-C/cisplatin; IFN,
interferon; MP, melphalan/prednisolone; T, thalidomide; TD, thalidomide/dexamethasone; VAD, vincristine/doxorubicin/dexamethasone. 
� Performed
cycles of bortezomib chemotherapy 
� Change of serum M-protein during bortezomib chemotherapy (before bortezomib chemotherapy�maximally
decreased amount of serum M-protein during bortezomib chemotherapy). 
�Abbreviations: PR, partial remission; NC, no change; PD, progressive
disease. 
‖Abbreviations: TTP, time to progression; (C) and (P) mean ‘censored’ and ‘progressed’, respectively. 
¶Abbreviations: OS, overall survival;
(A) and (D) mean ‘alive’ and ‘dead’ status at last follow-up. **Abbreviations: B2, 2 cycles of bortezomib; BD2, 2 cycles of bortezomib/dexametha-
sone; BD4, 4 cycles of bortezomib/dexamethasone. 
� � This patient (case 6) had 3.2 g/dL of serum M-protein before bortezomib treatment. After 2
cycles of bortezomib, M-protein decreased to 2.7 g/dL (NC). When dexamethasone was added, however, M-protein decreased to 0.3 g/dL after
additional 4 cycles of bortezomib/dexamethasone (PR).
OS
¶
(months)
TTP
‖
(months)
Response
� M-protein
(g/dL)
� Cycle
� Start of 
bortezomib
Treatment*
Initial
stage
Date of
diagnosis
Age (yr)/
sex
Case
1 M/67 2002. 12. IIIB VAD�TD�B�CD�APBSCT 2003. 12. 4 3.7�0.9 PR 4.2 (P) 10.5 (A)
2 M/67 2000. 6. IIIA CD�VAD�APBSCT�IFN�TD�B 2004.4. 2 5.3�0.8 PR 6.4 (C) 6.4 (A)
3 M/59 2003. 1. IIIA VAD�APBSCT�TD�B�APBSCT 2004.2. 1 4.8�2.2 PR 1.5 (C) 8.1 (A)
4 M/58 2002. 11. IIIA VAD�TD�EDAP�B�BD 2003.11. B2�BD2** 5.5�4.2 NC 5.1 (P) 5.5 (D)
5 F/57 2002. 8. IIIA VAD�APBSCT�TD�B�EDAP 2003.11. 2 2.3�1.8 NC 1.4 (C) 2.8 (D)
6 F/58 2000. 1. IIIA VAD�APBSCT�T�MP�DCEP�B�BD 2003.11. B2�BD4** 3.2�2.7�0.3
� � NC�PR 10.0 (P) 11.0 (A)
7 M/66 2001. 7. IIIA MP�VAD�CD�T�B 2004.2. 1 3.7�4.8 PD 0.6 (P) 1.1 (D)
Table 1. Summary of patient characteristics and treatment outcomes
AST, aspartate aminotransferase; ALT, alanine aminotransferase.
Cycles (n=20) %
Adverse events
All events Grade 3 events Grade 4 events
Thrombocytopenia 13 (65%) 4 (20%) 6 (30%)
Emesis 12 (60%) --
Leucopenia 12 (60%) --
Anemia 8 (40%) --
Peripheral neurotoxicity 8 (40%) 2 (10%) -
AST/ALT elevation 3 (15%) --
Constipation 1 (5%) --
Myalgia 1 (5%) --
Skin eruption 1 (5%) --
Peripheral edema 1 (5%) --
Table 2. Reported adverse eventsBortezomib in Multiple Myeloma 601
transcription of proteins that promote cell survival, stimulate
growth, and reduce susceptibility to apoptosis. Also, NF- B
activation induces drug resistance in myeloma cells (16). Borte-
zomib, a boronic acid dipeptide, reversibly inhibits protea-
some function by targeting the chymotrypsin-like site of the
proteasome (21) and has antitumor activity in a variety of in
vitro and in vivo models of tumors. It induces apoptosis in
myeloma-cell lines (22, 23). Molecular mechanisms of borte-
zomib entail more than NF- B inhibition (24, 25), and in
vivo, it enhances the anti-myeloma activity of chemothera-
peutic agents (24, 26).
Based on a phase I study of advanced hematologic cancer,
in which bortezomib showed activity in 9 patients with MM
(27), 2 phase II trials in relapsed or refractory myeloma were
reported until now (16, 17, 28). In these 2 studies, overall
response rate to bortezomib alone was 33-50% (16, 17). The
median duration of response in responders was 12.0 months
and median time to progression among all enrolled patients
was 7.0 months (16). The overall response rate of bortezomib
and/or dexamethasone was 44-62% (17). 
In this pilot study, overall response rate to bortezomib alone
was 43%, which was similar to previous reports, and 1 addi-
tional PR was achieved with the combination of bortezomib
and dexamethasone (case 6). Considering that all enrolled
patients previously received chemotherapy (±autologous
stem cell transplantation) and thalidomide, bortezomib seems
to be effective in chemotherapy and thalidomide-failed myelo-
ma patients. As previous reports, serious thrombocytopenia
and peripheral neuropathy were developed. The incidence
of grade 3 and 4 thrombocytopenia was 50% in this study.
This more frequent incidence of serious thrombocytopenia
than previous reports (16, 17) might be caused by patient
characteristics of this study, in which all of enrolled patients
received bortezomib as 3rd to 6th-line treatment and seemed
to have poor bone marrow functions. Median TTP in this
study, when bortezomib and/or dexamethasone were admin-
istered, was 5.1 months. These toxicity profiles and survival
data need to be determined in future larger studies on Korean
patients. 
Overall, bortezomib seems to be effective and feasible in
chemotherapy and thalidomide-failed myeloma patients with
the dosage of 1.3 mg per square meter twice weekly for 2
week in a 3-week cycle. These observations necessitate the
conduction of future larger clinical studies on Korean patients
to characterize clinical efficacy and safety of bortezomib more
precisely.
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